Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis

被引：0
|
作者：
Schwarzer, A. [1 ]
Schulte, C. [2 ]
Fries, S. [3 ]
Cavo, M. [4 ]
Tsukada, N. [5 ]
Tekle, C. [6 ]
Manasanch, E. E. [7 ]
Knauf, W. [8 ]
机构：
[1] Onkopraxis Probstheida, Leipzig, Germany
[2] Gemeinsch Praxis Hamatol & Onkol, Dortmund, Germany
[3] Onkol Schwerpunktpraxis, Bamberg, Germany
[4] Univ Bologna, IRCCS Azienda Osped, Ist Ematol, Bologna, Italy
[5] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
[6] Sanofi, Cambridge, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[8] Centrum Hamatol & Onkol Bethanien, Frankfurt, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1109
引用
收藏
页码：316 / 316
页数：1
相关论文
共 50 条
  • [41] A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
    Dileo, Rachel
    Mewawalla, Prerna
    Babu, Kalaivani
    Yin, Yue
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [42] A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/ Refractory Multiple Myeloma
    Frenking, Jan
    Riedhammer, Christine
    Besemer, Britta
    Braune, Jan
    Brioli, Annamaria
    Brunner, Franziska
    Dampmann, Maria
    Gezer, Deniz
    Goldman-Mazur, Sarah
    Haenel, Mathias
    Hanoun, Christine
    Hoegner, Marion
    Kolditz, Katja
    Kos, Igor
    Kull, Miriam
    Leitner, Theo
    Merz, Maximilan
    von Metzler, Ivana
    Michel, Christian S.
    Teipel, Raphael
    Theurich, Sebastian
    Waesch, Ralph
    Zukovs, Romans
    Rasche, Leo
    Raab, Marc-Steffen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S52 - S53
  • [43] Daratumumab, Bortezomib and Dexamethasone (DVd) at First Relapse for Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis
    McMillan, Annabel
    Basu, Supratik
    Karunanithi, Kamaraj
    Parkins, Elizabeth A.
    Lau, Edward
    Cook, Gordon
    Parrish, Christopher
    Al-Kaisi, Firas
    Pratt, Guy
    Shafeek, Salim
    Jenkins, Stephen William Hart
    Moosai, Shivir
    Memon, Danish
    Bygrave, Ceri A.
    Papanikolaou, Xenofon
    Maisel, Tara
    Hassan, Sandra
    Chander, Gurvin
    Kishore, Bhuvan
    Karim, Farheen
    Talbot, Georgina
    Wandroo, Farooq A.
    Bolarinwa, Dunsi
    Yong, Kwee
    Popat, Rakesh
    BLOOD, 2021, 138
  • [44] POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EXPERIENCE CENTER
    Cuesta Garcia, A.
    HAEMATOLOGICA, 2015, 100 : 104 - 104
  • [45] Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
    Razzo, Beatrice
    Grajales-Cruz, Ariel
    Atrash, Shebli
    Ferreri, Christopher
    Goyal, Anmol
    Pasvolsky, Oren
    Banerjee, Rahul
    Julian, Kelley
    Forsberg, Peter
    Herr, Megan
    Lin, Yi
    Susanibar-Adaniya, Sandra
    Khouri, Jack
    Vazquez-Martinez, Mariola
    Lee, Hans
    Portuguese, Andrew
    Sborov, Douglas W.
    Dima, Danai
    Davis, James
    Kaur, Gurbakhash
    Shune, Leyla
    Hansen, Doris
    Sidana, Surbhi
    Garfall, Alfred
    Richard, Shambavi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S82 - S83
  • [46] REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN US PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
    Nicacio, L. Viana
    Calkins, G.
    Curtis, M.
    Kohansimeh, J.
    Lindberg, F. P.
    Larrabee, K.
    Jaskiw, A.
    Feinstein, R. N.
    Terry, M.
    Plotkin, L.
    Palladino, M. L.
    Krishna, A.
    Green, R. J.
    HAEMATOLOGICA, 2015, 100 : 742 - 742
  • [47] Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience
    Zhou, Xin
    Xia, Jun
    Mao, Jingjue
    Cheng, Feng
    Qian, Xifeng
    Guo, Hongfeng
    HEMATOLOGY, 2016, 21 (05) : 280 - 286
  • [48] REAL-WORLD BORTEZOMIB USAGE PATTERNS AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Calkins, G.
    Kohansimeh, J.
    Krishna, A.
    Green, R. J.
    Curtis, M.
    Lindberg, F. P.
    Jaskiw, A.
    Larrabee, K.
    Terry, M.
    Feinstein, R. N.
    Plotkin, L.
    Palladino, M. L.
    Nicacio, L. Viana
    HAEMATOLOGICA, 2015, 100 : 742 - 742
  • [49] Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeannene
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne
    BLOOD, 2018, 132
  • [50] Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma
    Usami, Eiseki
    Kimura, Michio
    Takenaka, Shoya
    Iwai, Mina
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (02) : 293 - 298
12345